Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.35 |
| ▸ | CDK9 | P50750 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865647 | 0.90 | CCNT1 (0.34) | CSF1RDRD2DRD4DRD3CNR2 | |
| SCHEMBL17865701 | 0.86 | KMT2A (0.35) | CSF1RDRD2DRD4DRD3CCNT1 | |
| SCHEMBL17865677 | 0.78 | KMT2A (0.39) | CSF1RCCNT1CDK9MKNK1MKNK2 | |
| SCHEMBL17865680 | 0.76 | DRD2 (0.33) | CSF1RDRD2DRD4DRD3CNR2 | |
| SCHEMBL17865685 | 0.76 | CCNT1 (0.34) | CNR2CCNT1CDK9 | |
| SCHEMBL3011556 | 0.73 | CSF1R (0.53) | CSF1RCCNT1CDK9MKNK1MKNK2 | |
| SCHEMBL17865653 | 0.71 | ALDH1A1 (0.37) | L3MBTL1KDM4E | |
| SCHEMBL17865698 | 0.71 | ALDH1A1 (0.35) | L3MBTL1KDM4ETDO2 | |
| SCHEMBL15005761 | 0.69 | CSF1R (0.32) | CSF1RCNR2CCNT1CDK9KDM4E | |
| SCHEMBL3019811 | 0.68 | LRRK2 (0.36) | CSF1RCNR2CDK9TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | claimed |
| EP-3037418-B1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2019-10-02 | — | — | EP | claimed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | claimed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| EP-3037418-B1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2019-10-02 | — | — | EP | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | CSF1R 2988/4885DRD2 1227/4885DRD4 1850/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | CSF1R 2352/4885DRD2 1056/4885DRD4 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.